Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 3
2008 4
2009 5
2010 1
2011 7
2012 3
2013 8
2014 7
2015 9
2016 6
2017 11
2018 9
2019 8
2020 4
2021 8
2022 9
2023 14
2024 11
2025 7
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, Barkati M, Bottomley DM, Brasso K, Chung HT, Chung PWM, Conroy R, Falconer A, Ford V, Goh CL, Heath CM, James ND, Kim-Sing C, Kodavatiganti R, Malone SC, Morris SL, Nabid A, Ong AD, Raman R, Rodda S, Wells P, Worlding J, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2416-2425. doi: 10.1016/S0140-6736(24)00549-X. Epub 2024 May 16. Lancet. 2024. PMID: 38763153 Free PMC article. Clinical Trial.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, Anderson J, Barkati M, Bottomley DM, Branagan J, Choudhury A, Chung PWM, Cogley L, Goh CL, Hoskin P, Khoo V, Malone SC, Masters L, Morris SL, Nabid A, Ong AD, Raman R, Tarver KL, Tree AC, Worlding J, Wylie JP, Zarkar AM, Parulekar WR, Parmar MKB, Sydes MR; RADICALS investigators. Parker CC, et al. Lancet. 2024 Jun 1;403(10442):2405-2415. doi: 10.1016/S0140-6736(24)00548-8. Epub 2024 May 16. Lancet. 2024. PMID: 38763154 Free PMC article. Clinical Trial.
Barriers That Interfere with Access to Tuberculosis Diagnosis and Treatment across Countries Globally: A Systematic Review.
Teibo TKA, Andrade RLP, Rosa RJ, de Abreu PD, Olayemi OA, Alves YM, Vaz Tavares RB, da Costa FBP, Dias Moura HS, Ferezin LP, Tártaro AF, de Campos MCT, Ribeiro NM, Berra TZ, Arcêncio RA. Teibo TKA, et al. Among authors: de campos mct. ACS Infect Dis. 2024 Aug 9;10(8):2600-2614. doi: 10.1021/acsinfecdis.4c00466. Epub 2024 Jul 18. ACS Infect Dis. 2024. PMID: 39023509 Free PMC article.
[Prädiktive Faktoren für Anti-MDA5-Antikörper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie].
Castellanos-Gonzalez M, Bris BB, Marsol IB, Campos MM, Ruiz-Villaverde R, Llorente CP, Nuno-Gonzalez A, Sánchez JT, Mur EC, García RG, Alonso AB, Español GA, García YH, Schmidt JMS, Sánchez MA, Crespo ER, Alonso ELH, Gallo-Pineda G, Izquierdo JAA, Varillas-Delgado D. Castellanos-Gonzalez M, et al. Among authors: campos mm. J Dtsch Dermatol Ges. 2023 Jul;21(7):741-750. doi: 10.1111/ddg.15089_g. J Dtsch Dermatol Ges. 2023. PMID: 37427730 German.
Development and internal validation of a multifactorial risk prediction model for gallbladder cancer in a high-incidence country.
Boekstegers F, Scherer D, Barahona Ponce C, Marcelain K, Gárate-Calderón V, Waldenberger M, Morales E, Rojas A, Munoz C, Retamales J, de Toro G, Barajas O, Rivera MT, Cortés A, Loader D, Saavedra J, Gutiérrez L, Ortega A, Bertrán ME, Bartolotti L, Gabler F, Campos M, Alvarado J, Moisán F, Spencer L, Nervi B, Carvajal-Hausdorf D, Losada H, Almau M, Fernández P, Olloquequi J, Fuentes-Guajardo M, Gonzalez-Jose R, Bortolini MC, Acuña-Alonzo V, Gallo C, Linares AR, Rothhammer F, Lorenzo Bermejo J. Boekstegers F, et al. Among authors: campos m. Int J Cancer. 2023 Sep 15;153(6):1151-1161. doi: 10.1002/ijc.34607. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260300
127 results